Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tercica’s Somatuline Depot approved for acromegaly

Executive Summary

Somatuline Depot (lanreotide) will launch in approximately two months, Tercica says following FDA's Aug. 30 approval for treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The company is aiming to achieve $100 million in sales by 2010, which, based on a target market of 4,000 patients, would translate to pricing in the range of $25,000 per patient. Somatuline Depot will compete with Novartis' long-acting treatment Sandostatin LAR (octreotide), which accounts for the majority of the U.S. acromegaly market...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel